tiprankstipranks
InnoCan Pharma Advances Veterinary CBD Drug with FDA Nod
Company Announcements

InnoCan Pharma Advances Veterinary CBD Drug with FDA Nod

Story Highlights

InnoCan Pharma (TSE:INNO) has released an update.

Pick the best stocks and maximize your portfolio:

InnoCan Pharma has achieved a crucial milestone in veterinary medicine by obtaining an Investigational New Animal Drug (INAD) number from the FDA for its LPT-CBD product, designed for prolonged-release CBD in animal pain management. The FDA’s recognition of InnoCan’s innovative animal drug technology also came with a sponsor fee waiver for the fiscal year 2024, indicating strong support for the company’s ongoing development in this field.

For further insights into TSE:INNO stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskInnocan Pharma Announces C$700K Private Placement
TipRanks Canadian Auto-Generated NewsdeskInnoCan Pharma Achieves Key Milestones in 2024
TipRanks Canadian Auto-Generated NewsdeskInnocan Pharma Reports Positive Safety Results
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App